Third Wave Technologies, Inc. engages in the development and marketing of molecular diagnostic products for various DNA and RNA analysis applications. It provides physicians and researchers with molecular solutions for the analysis and treatment of disease. The company offers products based proprietary Invader chemistry, a technology used in women's health, infectious disease, genetics and pharmacogenetics, and oncology segments. Third Wave principally offers inVitro diagnostic devices and analyte specific reagents. The company's analyte specific reagents allow laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing, and a host of other mutations associated with genetic predispositions and other diseases. Third Wave also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Third Wave sells its products through a combination of direct sales personnel who focuses primarily on the clinical market, as well as through collaborative relationships in the United States and Europe. The company was founded in 1993 and is headquartered in Madison, Wisconsin. As of July 23, 2008, Third Wave Technologies Inc. operates as a subsidiary of Hologic Inc.

Panzhihua Xingchen Vanadium and Titanium Co., Ltd., established on 2003-11-28, Business scope includes vanadium,titanium,ferroalloy production,processing,Sales;Import and export business of the company's products and raw materials;new energy,Research and development of new materials,Production,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shijiazhuang Yiling Pharmaceutical develops, produces, and sells patent medicines. The product portfolio includes traditional medicine, health care products, western formulations, and TCM slices, among others. They supply, introduce advanced equipment and pharmaceutical technology both domestically and internationally, and develop a quality control system.

Yaoyanshe is a CRO technology platform. They provide CRO services such as clinical monitoring, project management, registration affairs, biostatistics, pharmacovigilance, and medical affairs. They also provide SMO services. Yaoyanshe addresses the industry's most pressing issues and advances the objective of more effective pharmaceutical research and development.

Sichuan Medical Shun Technology Co., Ltd., established on 2016-07-18, Business scope includes research and development of medical and pharmaceutical technology;Technical Services,technology development,technical consulting,Technology Promotion;Medical Consulting Services(Does not include health care activities);Information Technology Development;Medical Research and Experimental Development;Nutrition and Health Consulting;Computer Information Technology Services;Information system operation and maintenance services;software development;Information system integration service;Artificial intelligence basic resources and technology platform;Artificial intelligence general application system;internet data service;AI Hardware Sales;Retailing of computer software, hardware and auxiliary equipment;Information security equipment sales;Wearable smart device sales;electronics sales;animation design;computer animation design;multi-media design;Radio and television program production(Did not obtain the relevant administrative license(approval),Do not carry out business activities);Planning creative services;translation service;Educational Consulting(Education and training activities that do not include licensing approval);Value-added Telecom Services(Did not obtain the relevant administrative license(approval),Do not carry out business activities);Computer and Office Equipment Repair;computer,communication equipment(Excluding wireless broadcasting and television transmitting and satellite ground receiving equipment)lease;Business Consulting(No Securities,futures,Financial and investment consulting);Technical extension services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Dr. Falk Pharma GmbH engages in the development and sale of medication for indications in hematology and gastroenterology in Germany and internationally. The company principally offers prescription drugs that are used in treating inflammatory bowel diseases, cholestatic liver diseases, irritable bowel syndromes, and constipation, as well as for colon cleansing prior to colonoscopies. It also organizes and sponsors medical education events; and offers publications for healthcare professionals, as well as for patients and their families. The company was formerly known as Dr. Falk Arzneimittel GmbH & Co KG and changed its name to Dr. Falk Pharma GmbH in 1989. Dr. Falk Pharma GmbH was founded in 1960 and is headquartered in Freiburg, Germany

Hebei Yiling Pharmaceutical Research Institute Co., Ltd., established on 2001-04-19, Business scope includes Chinese patent medicine,Medicine and health products,Traditional Medical Devices,Western medicine,Biological product,Research and Development of Sanitary Dressing;technical consulting,Serve,transfer.(Those requiring special approval shall not operate without approval)

Suzhou Haike Medical Technology Co., Ltd., established on 2015-01-14, Business scope includes biotechnology development,Bioassay Technology Services,account Serive.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shuguang Hospital is a private company headquartered in Shanghai, China, that operates as a hospital.

Part of CSPC Pharmaceutical Group Ltd., CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. is a company headquartered in China. The firm engages in pharmaceutical research and development.

Oracle America, Inc. provides network computing infrastructure solutions. The company was founded in 1982 and is headquartered in Redwood City, CA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Dongguk University Industry-Academic Cooperation Foundation is for the promotion of tenants and entrepreneurship.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Laboratorios Silanes SA de CV manufactures and sells pharmaceutical products. The company engages in the development of pharmaceuticals. It offers various prescription products in therapeutic areas, such as multivitamins, cardiovascular diseases, diabetes, and anti-inflammatory medicines. The company was founded in 1943 and is headquartered in Mexico City, Mexico.

Acurian, Inc. provides clinical trial patient recruitment and retention solutions for the life sciences industry. It offers recruitment feasibility, site identification and selection, patient recruitment and retention services. The firm also provides the recruitment manager platform or database that features feasibility and project management capabilities. The company was founded by Lance D. Converse, David Restrepo and Leslie D. Michelson in 1998 and is headquartered in Horsham, PA.

South Texas Accelerated Research Therapeutics LLC is a global phase research organization focused on accelerating the development of new anticancer drugs with the purpose of improving life and survival of patients with cancer. The company was founded by Anthony W. Tolcher, Amita Patnaik and Kyriakos P. Papadopoulos and is headquartered in San Antonio, TX.

Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.